Clinical Trials Logo
  1. Home
  2. Cystinosis
  3. NCT00822250
  4. Details
NCT00822250 Clinical Trial

Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis

Cystinosis Clinical Trial

Official title:
Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00822250
Other study ID # 07-PP-05
Secondary ID
Status Completed
Phase N/A
First received January 13, 2009
Last updated October 20, 2010
Start date April 2008
Est. completion date December 2009

Study information
Verified date October 2010
Source Centre Hospitalier Universitaire de Nice
Contact n/a
Is FDA regulated No
Health authority France: Direction Générale de la SantéFrance: Institutional Ethical Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the molecular mechanism of this disease and to research the relationship between cystinosis and skin phenotype.

Recruitment information / eligibility
Status Completed
Enrollment 30
Est. completion date December 2009
Est. primary completion date December 2009
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 15 Years
Eligibility Inclusion Criteria:

1. cystinosis

2. known CTNS mutation

Exclusion Criteria:

1. patient with corticotherapy treatment

2. patient with immunosuppressant treatment

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Intervention

Other:
• analysis of pigmentation
cutting hair, skin description, skin biopsy for only 4 patients

Locations
Country Name City State
France department of dermatology, Nice University Hospital Nice

Sponsors (1)
Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary to determine molecular mechanism of the disease at time= 0 No
Secondary to research relationship between skin phenotype and cystinosis at time =0 No
See also
  Status Clinical Trial Phase
Recruiting NCT05545774 - Neuromuscular Characterisation in Late Adolescent and Adult Cystinosis Patients
Completed NCT01432561 - Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™ N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT04125927 - Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2) Phase 3
Completed NCT00071903 - The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study N/A
Recruiting NCT05994534 - PK and PD Study of NPI-001 and Cysteamine Bitartrate Phase 1/Phase 2
Completed NCT00004350 - Evaluation of Fanconi Syndrome and Cystinosis N/A
Completed NCT00004312 - Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT02533076 - The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients Phase 0
Enrolling by invitation NCT05146830 - A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04
Completed NCT00872729 - Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis Phase 1/Phase 2
Completed NCT00001736 - New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis Phase 1
Recruiting NCT05959668 - Development of Health-related Quality of Life Instrument for Patients With Cystinosis
Withdrawn NCT02124070 - Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis Phase 1/Phase 2
Completed NCT01614431 - N Acetyl Cysteine for Cystinosis Patients Phase 4
Recruiting NCT05843851 - Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria N/A
Completed NCT01000961 - Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis Phase 3
Active, not recruiting NCT03897361 - Stem Cell Gene Therapy for Cystinosis Phase 1/Phase 2